AWM Investment Company Inc. Sells 185,906 Shares of Sera Prognostics, Inc. $SERA

AWM Investment Company Inc. lessened its position in Sera Prognostics, Inc. (NASDAQ:SERA) by 21.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 680,931 shares of the company’s stock after selling 185,906 shares during the quarter. AWM Investment Company Inc. owned about 1.81% of Sera Prognostics worth $1,886,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Abel Hall LLC bought a new stake in Sera Prognostics during the second quarter valued at about $31,000. Wagner Wealth Management LLC bought a new stake in Sera Prognostics during the 2nd quarter valued at approximately $34,000. Riverview Capital Advisers LLC bought a new stake in Sera Prognostics during the 2nd quarter valued at approximately $35,000. XTX Topco Ltd acquired a new stake in Sera Prognostics in the 1st quarter valued at approximately $39,000. Finally, Qube Research & Technologies Ltd bought a new position in Sera Prognostics in the 2nd quarter worth approximately $92,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Trading Up 3.2%

Shares of NASDAQ:SERA opened at $3.51 on Friday. The firm has a market capitalization of $135.49 million, a PE ratio of -4.56 and a beta of 0.97. Sera Prognostics, Inc. has a 1-year low of $1.37 and a 1-year high of $9.13. The business’s 50 day moving average is $3.19 and its 200-day moving average is $2.80.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Thursday, November 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. Sera Prognostics had a negative return on equity of 41.69% and a negative net margin of 34,343.16%.The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, sell-side analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Wall Street Analyst Weigh In

SERA has been the subject of several research reports. Wall Street Zen raised Sera Prognostics from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Sera Prognostics has a consensus rating of “Sell”.

Insiders Place Their Bets

In related news, CEO Zhenya Lindgardt sold 28,215 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $3.04, for a total value of $85,773.60. Following the completion of the transaction, the chief executive officer owned 768,081 shares of the company’s stock, valued at $2,334,966.24. This represents a 3.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 50,587 shares of company stock valued at $157,528 over the last quarter. Insiders own 13.50% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.